<DOC>
	<DOCNO>NCT01741285</DOCNO>
	<brief_summary>We hypothesize extra-fine particle treatment HFA-QVAR superior improve small airway dysfunction , especially ex-smokers smoker asthma . To investigate , perform study compare efficacy extra-fine particle HFA-QVAR 200 µg b.i.d . equipotent dose course particle HFA-beclomethasone ( HFA-Clenil ) 400 µg b.i.d . coarse particle HFA-fluticasone ( GSK ) 250 µg ex-smokers smoker asthma . Study design : This study open-label , randomise , three-way cross-over , two-center study . 20 smoker 20 ex-smokers asthma receive follow treatment two week :</brief_summary>
	<brief_title>Effects QVAR Smokers With Asthma</brief_title>
	<detailed_description>Rationale : Thus far , clinical study investigate effect inhale corticosteroid ( ICS ) asthma concentrate non-smoking asthmatic . However , considerable proportion asthma patient smoke . Cigarette smoke consist ultra-fine particle diameter 0.1 1 µm therefore reach even small airway . In line , report smoking associate small airway dysfunction . The latter may help explain observation treatment course particle inhale corticosteroid less effective smoker asthma . Recently , extra-fine particle aerosols hydrofluoroalkane-beclomethasone ( HFA-QVAR ) become available treatment asthma , likely reach small airway . Based , hypothesize extra-fine particle treatment HFA-QVAR superior improve small airway dysfunction , especially ex-smokers smoker asthma . Objective : To perform study compare efficacy extra-fine particle HFA-QVAR 200 µg b.i.d . equipotent dose course particle HFA-beclomethasone ( HFA-Clenil ) 400 µg b.i.d . coarse particle HFA-fluticasone ( GSK ) 250 µg ex-smokers smoker asthma . Study design : This study open-label , randomise , three-way cross-over , two-center study . 20 smoker 20 ex-smokers asthma receive follow treatment two week : Treatment period A : 2-week treatment HFA-QVAR ( TEVA Pharma ) 200 μg b.i.d . Treatment period B : 2-week treatment HFA-Clenil ( Chiesi ) 400 μg b.i.d . Treatment period C : 2-week treatment HFA-Fluticasone ( GlaxoSmithKline ) 250 μg b.i.d . Study population : 20 smoker 20 ex-smokers asthma , age 18-65 year , receive follow treatment two week : Intervention ( applicable ) : A : 2-week treatment HFA-QVAR ( TEVA ) 200 μg b.i.d . B : 2-week treatment HFA-Clenil ( Chiesi ) 400 μg b.i.d . C : 2-week treatment HFA-Fluticasone ( GlaxoSmithKline ) 250 μg b.i.d . Main study parameters/endpoints : The primary end-parameter decrease peripheral airway resistance ( R5-R20 ) provocative dose small particle adenosine cause Forced Expiratory Volume one second ( FEV1 ) drop 20 % . The co-primary end-parameter PD20 small particle adenosine . All patient attend 7 visit outpatient clinic . At baseline treatment , follow investigation perform : PC20AMP , PD20 small particle adenosine , spirometry , IOS , body plethysmography , blood collection , fill questionnaire , nasal epithelial brushing .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>3.1 Inclusion criterion In order eligible participate study , subject must meet following criterion : Males females doctor 's diagnosis asthma Age 18 65 year Current exsmokers ≥ 5 packyears . Drop FEV1 &gt; 20 % provocation small particle adenosine &lt; 20 mg visit 1 . 3.2 Exclusion criterion A subject meet follow criterion exclude participation study : An asthma exacerbation last 6 week upper respiration tract infection last 4 week prior inclusion study . Severe airway obstruction baseline , FEV1 &lt; 50 % predict &lt; 1.2 liter . Physician diagnose predominant COPD pulmonary disease could influence study result judge investigator . Pregnant lactating woman . Females childbearing potential without efficient contraception unless meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL use one follow acceptable method contraception : 1 . Surgical sterilization ( e.g . bilateral tubal ligation , hysterectomy ) . 2 . Hormonal contraception ( implantable , patch , oral , injectable ) . 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/cream/suppository . 4 . Continuous abstinence . Periodic abstinence ( e.g . calendar , ovulation , symptomthermal , postovulation method ) withdrawal acceptable method contraception . Reliable contraception maintain throughout study 30 day study drug discontinuation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Adenosine</keyword>
	<keyword>Small airway</keyword>
	<keyword>Smokers</keyword>
	<keyword>Ex-smokers</keyword>
</DOC>